Log In
BCIQ
Print this Print this
 

TT-223 + EGF (formerly E1-I.N.T.)

Also known as: Islet Neogenesis Therapy

  Manage Alerts
Collapse Summary General Information
Company Opko Health Inc.
DescriptionInjection of gastrin and epidermal growth factor (EGF) analog
Molecular Target Cholecystokinin B receptor (CCKBR) (CCK2R) ; Epidermal growth factor receptor 1 (EGFR1) (HER1) (ErbB1)
Mechanism of ActionEpidermal growth factor (EGF) receptor agonist; Gastrin receptor agonist
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationDiabetes
Indication DetailsTreat diabetes; Treat Type I diabetes; Treat Type II diabetes
Regulatory Designation
PartnerEli Lilly and Co.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$60.0M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

08/31/2016

$60.0M

0

0

Get a free BioCentury trial today